Patients & Caregivers
New Data Shows Positive Effects of BLU-285 in Gastrointestinal Tumors
New Phase 1 clinical data for BLU-285 supports previous data that demonstrated the drug as exhibiting strong clinical activity and an encouraging safety profile.
Sprycel Approval Expanded to Include Treatment of Children with Rare Chronic Myeloid Leukemia Variation
Bristol-Myers Squibb announced that the FDA has expanded its approval of Sprycel tablets. The new indication includes children with rare chronic myeloid leukemia.
FDA Approves Adcetris for Rare Skin Cancers
Adcetris (brentuximab vedotin) approved to treat 2 rare skin cancer: pcALCL and CD30 positive MF
Ghassan Abou-Alfa, MD Discusses Fibrolamellar Cancer
Ghassan Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, specializes in gastrointestinal cancers.
Being Afraid to Dream: Life with Chemotherapy-Induced Hearing Loss
Everybody else is figuring out what they want to do for a job, school, vacations. And I'm barely getting through every single day.
A Parent's Silent Prayer: Preventing Hearing Loss for Childhood Cancer Survivors
While hearing loss is just 1 of multiple side effects that many risk cancer survivors experience, this loss touches almost every aspect of one’s life.
Cancer Research Institute CEO Explains Immunotherapy in Rare Cancers
Jill O'Donnell-Tormey, PhD, discusses immunotherapy and the immune system's role in rare cancers.
Ignyta Chairman and CEO: Entrectinib Has A Really Good Shot
Rare Disease Report
recently spoke with Jonathan Lim, M.D., the Chairman and CEO of Ignyta about the exciting results and next steps for Entrectinib.
Rare Lung Cancer Drug Approved by FDA
The FDA announced the granting of regular approval to Alecensa (alectinib) for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
FDA Grants Approval to Zelboraf for Certain Patients with Rare Blood Disease
Today, it was announced that Zelboraf received expanded approval for the drug to include the treatment of adult patients with Erdheim-Chester disease whose cancer cells have the BRAF V600 mutation.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.